The question is not whether testosterone is safe for women in one word.
The better question is: which woman, which indication, which route, which dose, which blood level, which baseline risk, and for how long?
A 2019 systematic review and meta-analysis of 36 randomized trials with 8,480 participants found that testosterone improved sexual-function outcomes in postmenopausal women and did not increase serious adverse events in the available trial data. It also found more acne and hair growth, and oral testosterone worsened lipid measures compared with non-oral routes. [1]
That is useful short-term reassurance for studied use. It is not evidence that all testosterone products, doses, or long-term exposures are cardiovascularly neutral.
Bottom line
For women after menopause, testosterone belongs in a narrow evidence category: postmenopausal hypoactive sexual desire disorder after biopsychosocial assessment, when modifiable causes have been reviewed and dosing can stay within the physiologic premenopausal female range. [2] [3]
Cardiovascular safety depends on the details. A doseable non-oral product used with baseline total testosterone, follow-up levels, side-effect monitoring, lipid/liver context, and a stop rule is a different risk posture from oral testosterone, pellets, injections, unclear compounded dosing, or a clinic chasing supraphysiologic "optimization." [1] [3] [4]
An eligibility-aware assessment is useful because the same "testosterone for women" label can hide very different risk profiles: low-risk postmenopausal hypoactive sexual desire disorder with monitored transdermal dosing, versus high low-density lipoprotein, diabetes, hypertension, smoking, prior clot, coronary disease, pellet dosing, or treatment for a non-evidence-based goal.
What the trial data can and cannot establish
The 2019 meta-analysis is the anchor because it is broad and specific. It pooled randomized trials in women and found sexual-function benefits, especially in postmenopausal women, but it also reported androgenic side effects and unfavorable lipid effects with oral testosterone. [1]
| Evidence point | What it supports | What it does not establish |
|---|---|---|
| 36 randomized trials and 8,480 participants | Testosterone can improve sexual-function outcomes in selected women. [1] | Testosterone treats fatigue, weight, cognition, or general well-being. |
| No serious-adverse-event increase in trial data | Short-term studied use did not show a clear serious-harm signal. [1] | Long-term heart attack, stroke, and lifelong exposure risk are settled. |
| Oral route worsened lipid measures | Route matters and oral testosterone is less attractive for routine hypoactive sexual desire disorder care. [1] | Every non-oral route is automatically safe. |
| Acne and hair growth were more common | Androgenic effects need monitoring. [1] | Side effects are just cosmetic or irrelevant. |
| Guidance centers hypoactive sexual desire disorder | The indication is narrow. [2] [3] | Testosterone is a broad menopause, metabolic, or cardiovascular treatment. |
The evidence is limited in the most important cardiovascular way: most trials were built to measure sexual outcomes, not powered hard cardiovascular outcomes such as myocardial infarction, stroke, venous thromboembolism, cardiovascular death, or long-term outcomes in high-risk women.
Route and dose are part of cardiovascular safety
Guideline-based women's testosterone care is not "more is better." The endpoint is symptom benefit without supraphysiologic exposure.
The Global Consensus Position Statement supports testosterone only for postmenopausal women with hypoactive sexual desire disorder after formal assessment and cautions against products that produce blood levels above the usual female range. [2]
International Society for the Study of Women's Sexual Health guidance recommends systemic transdermal testosterone for women with hypoactive sexual desire disorder not primarily related to modifiable factors or comorbidities. It uses total testosterone for baseline and monitoring, not to diagnose hypoactive sexual desire disorder by itself, and recommends monitoring to avoid supraphysiologic exposure. [3]
A 2025 ALEG position statement reaches the same practical boundary: testosterone for postmenopausal women should be limited to hypoactive sexual desire disorder confirmed through formal biopsychosocial evaluation, transdermal routes are preferred, and pellets plus compounded "bioidentical" testosterone are not recommended because of supraphysiologic dosing risk and insufficient evidence. [4]
| Route or exposure | Cardiovascular/lipid posture |
|---|---|
| Doseable non-oral physiologic exposure | Closest to the evidence-supported hypoactive sexual desire disorder category when monitored. [1] [3] |
| Oral testosterone | Less favorable lipid effects in trial meta-analysis. [1] |
| Pellets | Harder to reverse or titrate; not recommended in 2025 ALEG because of supraphysiologic dosing risk and insufficient evidence. [4] |
| Compounded products | International Society for the Study of Women's Sexual Health says compounded testosterone cannot be recommended due to insufficient efficacy and safety data. [3] |
| Injections | Peaks/troughs and dosing precision can complicate keeping levels in the female physiologic range. |
| Supraphysiologic levels | Outside the main evidence category; raises androgenic and monitoring concerns. [2] [3] |
Lipids and baseline risk change the conversation
Lipids are not a side issue. They are one of the clearest measurable differences by route in the evidence base. Oral testosterone's unfavorable lipid effects are one reason it is not the preferred routine path for women with hypoactive sexual desire disorder. [1]
International Society for the Study of Women's Sexual Health guidance includes liver function and a fasting lipid profile before treatment. It also recommends baseline total testosterone so follow-up can prevent excessive exposure. [3]
| Baseline factor | Why it matters before prescribing |
|---|---|
| High low-density lipoprotein or low high-density lipoprotein | Route and lipid monitoring become more important. |
| Diabetes, insulin resistance, or metabolic syndrome | Baseline cardiovascular risk is higher; do not add hormone uncertainty casually. |
| Hypertension or smoking | Absolute cardiovascular risk changes the risk-benefit discussion. |
| Prior clot, stroke, TIA, heart attack, or coronary disease | May push the decision toward specialist review or away from therapy. |
| Liver disease or abnormal liver tests | Important because guidance includes liver context before therapy. [3] |
| No diagnosed hypoactive sexual desire disorder | Risk uncertainty is not justified for a non-evidence-based target. [2] [5] |
The weaker the indication, the less cardiovascular uncertainty is acceptable.
Testosterone is not a cardiovascular prevention treatment
The Endocrine Society guideline recommends against diagnosing an androgen-deficiency syndrome in healthy women because the syndrome is not well defined and available data do not correlate androgen levels with specific signs or symptoms. It also recommends against general testosterone use for cardiovascular health, metabolic health, bone health, cognition, or general well-being. [5]
That matters because testosterone is sometimes marketed around energy, confidence, muscle, weight, cardiometabolic health, or aging. Those claims are not the evidence-supported female hypoactive sexual desire disorder category.
An observational claims-database study can be reassuring but should not be overread. One 2024 analysis reported no association between testosterone therapy in females and increased cardiovascular or breast cancer risk, but claims data cannot substitute for randomized long-term cardiovascular-outcome trials in well-defined menopausal hypoactive sexual desire disorder populations. [6]
Who this fits, and who should avoid shortcutting
This page fits a woman considering testosterone for postmenopausal hypoactive sexual desire disorder who wants to understand cardiovascular and lipid uncertainty before starting. It also fits someone already using testosterone whose clinician is reviewing lipids, blood pressure, product route, testosterone levels, side effects, and whether benefit is strong enough to continue.
It is a poor fit for reassurance shopping around pellets, supraphysiologic dosing, oral testosterone, bodybuilding-style dosing, male-dose products, or testosterone prescribed mainly for weight, energy, cognition, cardiometabolic health, or anti-aging.
Red flags and urgent symptoms
Chest pain, sudden shortness of breath, one-sided weakness, facial droop, speech difficulty, sudden severe headache, vision loss, fainting, or one-sided leg swelling needs urgent evaluation. Do not assume testosterone is or is not the cause at home.
Treatment-specific red flags include unexpectedly high testosterone levels, worsening blood pressure, abnormal lipids that change the risk-benefit balance, severe acne, rapid facial hair growth, scalp hair acceleration, voice change, clitoral symptoms, or a clinic that dismisses side effects while increasing dose.
What to ask a clinician
- Is testosterone being considered for formally assessed postmenopausal hypoactive sexual desire disorder, or for energy, weight, mood, cognition, or general wellness?
- What is my baseline cardiovascular risk: blood pressure, low-density lipoprotein, high-density lipoprotein, triglycerides, diabetes status, smoking, family history, and prior clot or stroke history?
- Is my planned route oral, transdermal, injectable, pellet, or compounded, and how does that change lipid and monitoring risk?
- What baseline labs are needed: total testosterone, sex hormone-binding globulin if relevant, fasting lipid profile, liver function, and any cardiometabolic tests?
- What testosterone level is too high, and when will levels be rechecked?
- What benefit endpoint confirms treatment is worth continuing?
- What symptoms or lab changes would make us lower the dose, stop treatment, or choose a non-testosterone plan?
Reviews of female sexual-dysfunction treatment continue to place testosterone in an hypoactive sexual desire disorder-specific decision category, which reinforces the cardiovascular point: the indication has to be strong enough to justify monitoring and uncertainty. [7]
Related reading:
- Testosterone blood tests after menopause.
- Testosterone therapy for women after menopause.
- Testosterone side effects in women.
- Testosterone cypionate for women.
- Testosterone and breast cancer risk after menopause.
References
[1] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[2] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[3] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[4] Pilnik S, Belardo A, Marchesan LB, et al. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG). Climacteric. 2025;28(5):529-536. doi:10.1080/13697137.2025.2548805 https://pubmed.ncbi.nlm.nih.gov/40919649/
[5] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/
[6] Agrawal P, Singh SM, Hsueh J, et al. Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis. J Sex Med. 2024;21(5):414-419. doi:10.1093/jsxmed/qdae032 https://pubmed.ncbi.nlm.nih.gov/38459625/
[7] Ingram CF, Payne KS, Messore M, Scovell JM. Testosterone therapy and other treatment modalities for female sexual dysfunction. Curr Opin Urol. 2020;30(3):309-316. doi:10.1097/mou.0000000000000759 https://pubmed.ncbi.nlm.nih.gov/32205812/
[8] MedlinePlus Medical Encyclopedia. Chest pain. https://medlineplus.gov/ency/article/003079.htm
[9] Centers for Disease Control and Prevention. Signs and symptoms of stroke. https://www.cdc.gov/stroke/signs-symptoms/index.html
[10] MedlinePlus Medical Encyclopedia. Breathing difficulties - first aid. https://medlineplus.gov/ency/article/000007.htm